Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.

ABSTRACT: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with a prevalence of approximately 1 in 1000. Over the last 30 years, advances in treatment such as use of corticosteroids and immunosuppressants have improved life expectancy and quality of life for patients with lupus and the key unmet needs have therefore changed. With the reduced mortality from disease activity, development of cardiovascular disease (CVD) has become an increasingly important cause of death in patients with SLE. The increased CVD risk in these patients is partly, but not fully explained by standard risk factors, and abnormalities in the immune response to lipids may play a role. Invariant natural killer T cells, which are triggered specifically by lipid antigens, may protect against progression of sub

SUBMITTER: Bakshi J 

PROVIDER: S-EPMC6244922 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature